Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orthovita to submit Orthocomp bone cement 510(k) in second quarter.

This article was originally published in The Gray Sheet

Executive Summary

ORTHOVITA's ORTHOCOMP BONE CEMENT 510(K) SUBMISSION for use in non-load bearing applications is scheduled for the second quarter, according to the firm. Speaking at a Jan. 27 session of the Rodman and Renshaw musculoskeletal devices conference in Boston, Senior VP Samuel Nalbone said the firm hopes the bioactive, self-setting bone bonding composite will "replace" polymethylmethacrylate (PMMA) cement due to its superior mechanical properties, biological bone-bonding interface and simple delivery and mixing system.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel